256 related articles for article (PubMed ID: 15127079)
1. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder.
Young AH; Gallagher P; Watson S; Del-Estal D; Owen BM; Ferrier IN
Neuropsychopharmacology; 2004 Aug; 29(8):1538-45. PubMed ID: 15127079
[TBL] [Abstract][Full Text] [Related]
2. Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia.
Gallagher P; Watson S; Smith MS; Ferrier IN; Young AH
Biol Psychiatry; 2005 Jan; 57(2):155-61. PubMed ID: 15652874
[TBL] [Abstract][Full Text] [Related]
3. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia.
Mackin P; Gallagher P; Watson S; Young AH; Ferrier IN
Aust N Z J Psychiatry; 2007 Apr; 41(4):321-6. PubMed ID: 17464718
[TBL] [Abstract][Full Text] [Related]
4. Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia.
Gallagher P; Watson S; Elizabeth Dye C; Young AH; Nicol Ferrier I
J Psychiatr Res; 2008 Oct; 42(12):1037-41. PubMed ID: 18255098
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression.
Watson S; Gallagher P; Porter RJ; Smith MS; Herron LJ; Bulmer S; ; Young AH; Ferrier IN
Biol Psychiatry; 2012 Dec; 72(11):943-9. PubMed ID: 22770649
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled, crossover trial of mifepristone in Gulf War veterans with chronic multisymptom illness.
Golier JA; Caramanica K; Michaelides AC; Makotkine I; Schmeidler J; Harvey PD; Yehuda R
Psychoneuroendocrinology; 2016 Feb; 64():22-30. PubMed ID: 26600007
[TBL] [Abstract][Full Text] [Related]
7. Clinical and biological effects of mifepristone treatment for psychotic depression.
Flores BH; Kenna H; Keller J; Solvason HB; Schatzberg AF
Neuropsychopharmacology; 2006 Mar; 31(3):628-36. PubMed ID: 16160710
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder.
McIntyre RS; Soczynska JK; Woldeyohannes HO; Miranda A; Vaccarino A; Macqueen G; Lewis GF; Kennedy SH
Bipolar Disord; 2012 Nov; 14(7):697-706. PubMed ID: 23107220
[TBL] [Abstract][Full Text] [Related]
9. Randomized placebo-controlled adjunctive study of an extract of withania somnifera for cognitive dysfunction in bipolar disorder.
Chengappa KN; Bowie CR; Schlicht PJ; Fleet D; Brar JS; Jindal R
J Clin Psychiatry; 2013 Nov; 74(11):1076-83. PubMed ID: 24330893
[TBL] [Abstract][Full Text] [Related]
10. Rapid reversal of psychotic depression using mifepristone.
Belanoff JK; Flores BH; Kalezhan M; Sund B; Schatzberg AF
J Clin Psychopharmacol; 2001 Oct; 21(5):516-21. PubMed ID: 11593077
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial.
Miskowiak KW; Ehrenreich H; Christensen EM; Kessing LV; Vinberg M
J Clin Psychiatry; 2014 Dec; 75(12):1347-55. PubMed ID: 25099079
[TBL] [Abstract][Full Text] [Related]
12. Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects.
Grossman R; Yehuda R; Golier J; McEwen B; Harvey P; Maria NS
Ann N Y Acad Sci; 2006 Jul; 1071():410-21. PubMed ID: 16891588
[TBL] [Abstract][Full Text] [Related]
13. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence.
Brown ES; Gorman AR; Hynan LS
J Clin Psychopharmacol; 2007 Oct; 27(5):498-502. PubMed ID: 17873684
[TBL] [Abstract][Full Text] [Related]
14. Cognitive effects of mifepristone in overweight, euthymic adults with depressive disorders.
Roat-Shumway S; Wroolie TE; Watson K; Schatzberg AF; Rasgon NL
J Affect Disord; 2018 Oct; 239():242-246. PubMed ID: 30025313
[TBL] [Abstract][Full Text] [Related]
15. Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia.
Ringen PA; Vaskinn A; Sundet K; Engh JA; Jónsdóttir H; Simonsen C; Friis S; Opjordsmoen S; Melle I; Andreassen OA
Psychol Med; 2010 Aug; 40(8):1337-47. PubMed ID: 19891810
[TBL] [Abstract][Full Text] [Related]
16. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial.
Saricicek A; Maloney K; Muralidharan A; Ruf B; Blumberg HP; Sanacora G; Lorberg B; Pittman B; Bhagwagar Z
J Clin Psychiatry; 2011 Jun; 72(6):744-50. PubMed ID: 21034692
[TBL] [Abstract][Full Text] [Related]
17. Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression.
Block T; Petrides G; Kushner H; Kalin N; Belanoff J; Schatzberg A
J Clin Psychopharmacol; 2017 Oct; 37(5):505-511. PubMed ID: 28708736
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
Thase ME; Macfadden W; Weisler RH; Chang W; Paulsson B; Khan A; Calabrese JR;
J Clin Psychopharmacol; 2006 Dec; 26(6):600-9. PubMed ID: 17110817
[TBL] [Abstract][Full Text] [Related]
19. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486.
Murphy BE; Filipini D; Ghadirian AM
J Psychiatry Neurosci; 1993 Nov; 18(5):209-13. PubMed ID: 8297920
[TBL] [Abstract][Full Text] [Related]
20. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression.
DeBattista C; Belanoff J; Glass S; Khan A; Horne RL; Blasey C; Carpenter LL; Alva G
Biol Psychiatry; 2006 Dec; 60(12):1343-9. PubMed ID: 16889757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
